Nyxoah S.A. (NASDAQ:NYXH - Free Report) - Stock analysts at HC Wainwright upped their Q1 2025 earnings per share estimates for Nyxoah in a research note issued on Wednesday, March 26th. HC Wainwright analyst E. White now expects that the company will post earnings of ($0.48) per share for the quarter, up from their prior estimate of ($0.50). HC Wainwright currently has a "Buy" rating and a $15.00 target price on the stock. The consensus estimate for Nyxoah's current full-year earnings is ($1.91) per share. HC Wainwright also issued estimates for Nyxoah's Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.25) EPS, FY2026 earnings at ($1.86) EPS and FY2027 earnings at ($0.58) EPS.
Separately, Stifel Nicolaus decreased their price objective on shares of Nyxoah from $16.00 to $15.00 and set a "buy" rating for the company in a report on Friday, March 14th.
View Our Latest Report on NYXH
Nyxoah Stock Down 0.9 %
NASDAQ:NYXH traded down $0.06 on Friday, hitting $6.92. 42,376 shares of the company's stock traded hands, compared to its average volume of 46,839. The firm has a 50-day moving average price of $10.27 and a 200-day moving average price of $9.36. The company has a current ratio of 5.28, a quick ratio of 4.95 and a debt-to-equity ratio of 0.21. The company has a market cap of $235.70 million, a PE ratio of -3.70 and a beta of 1.42. Nyxoah has a 1 year low of $6.76 and a 1 year high of $13.50.
Nyxoah (NASDAQ:NYXH - Get Free Report) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.03). Nyxoah had a negative return on equity of 51.68% and a negative net margin of 1,043.93%. The company had revenue of $1.35 million for the quarter, compared to the consensus estimate of $2.02 million.
Institutional Investors Weigh In On Nyxoah
Hedge funds have recently bought and sold shares of the company. Vestal Point Capital LP acquired a new stake in Nyxoah during the 4th quarter worth approximately $23,394,000. Ameriprise Financial Inc. bought a new stake in Nyxoah in the 4th quarter valued at $135,000. Walleye Capital LLC boosted its stake in Nyxoah by 23.9% in the 4th quarter. Walleye Capital LLC now owns 14,831 shares of the company's stock worth $119,000 after purchasing an additional 2,862 shares during the period. Renaissance Technologies LLC bought a new position in Nyxoah during the 4th quarter worth about $187,000. Finally, Geode Capital Management LLC raised its stake in shares of Nyxoah by 19.4% in the 4th quarter. Geode Capital Management LLC now owns 17,100 shares of the company's stock valued at $137,000 after purchasing an additional 2,774 shares during the period.
About Nyxoah
(
Get Free Report)
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
Featured Articles
Before you consider Nyxoah, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nyxoah wasn't on the list.
While Nyxoah currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
